# Saffron Depression Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/saffron-depression-meta-analysis-evidence-review
Category: evidence-review
Summary: Saffron Depression Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are system
Last reviewed: 2026-05-27
Reviewed by: Migaku Evidence Review
# Saffron Depression Meta-analysis: What the Evidence Says

## Quick Answer

Saffron Depression Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis | systematic review | 1 | 2026-01-01 | 10.4082/kjfm.24.0259 |
| The Role of Saffron in the Treatment of Depression: A Literature Review | preclinical study | 4 | 2026-03-03 | 10.7759/cureus.104594 |

## What The Sources Report

- A Swiss study found that 10% of participants experienced PMS, whereas 3% experienced PMDD. [Mohammadi Mohammad Mehdi (2026); evidence level 1]
- These challenges include legal issues, suicidal ideation, reduced work productivity, social isolation, parenting difficulties, increased absenteeism, disruptions of personal and social relationships, and frequent hospital visits. [Mohammadi Mohammad Mehdi (2026); evidence level 1]
- Depression is a leading cause of disability worldwide and is characterised by sustained low mood, anhedonia, anergia, and a range of associated cognitive and somatic symptoms . [Muacevic Alexander (2026); evidence level 4]
- This literature review summarises key randomised controlled trials (RCTs), meta-analyses, safety data, dosing patterns, and guideline positioning for saffron in depressive disorders, with emphasis on adult major depressive disorder (MDD) and related depressive symptomatology. [Muacevic Alexander (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For saffron depression meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Mohammadi Mohammad Mehdi (2026). Effect of saffron on premenstrual syndrome and dysmenorrhea: a systematic review and meta-analysis. DOI: 10.4082/kjfm.24.0259. PMCID: PMC12835668. PMID: 41151539. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC12835668/
- Muacevic Alexander (2026). The Role of Saffron in the Treatment of Depression: A Literature Review. DOI: 10.7759/cureus.104594. PMCID: PMC13044667. PMID: 41939549. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13044667/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.